UCB SA (UCB)

Currency in EUR
250.00
-9.20(-3.55%)
Closed·
UCB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
249.15258.70
52 wk Range
153.65289.50
Key Statistics
Prev. Close
259.2
Open
258
Day's Range
249.15-258.7
52 wk Range
153.65-289.5
Volume
353.45K
Average Volume (3m)
261.3K
1-Year Change
54.3686%
Book Value / Share
57.2
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
UCB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
288.95
Upside
+15.58%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth

UCB SA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

15 Buy
4 Hold
1 Sell
Ratings:
20 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 288.95
(+15.58% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Barclays
Hold300.00+20.00%310.00Downgrade15-06-2026
TD Cowen
Buy310.00+24.00%305.00Maintain13-03-2026
UBS
Buy330.00+32.00%300.00Maintain19-02-2026
Goldman Sachs
Buy304.00+21.60%255.00Maintain16-02-2026
TD Cowen
Buy300.00+20.00%-Maintain28-01-2026

Earnings

Latest Release
29-05-2026
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 8.03%
Dividend Yield
0.39%
Industry Median 0.63%
Annualised payout
1.02
Paid annually
5-Years Growth
+2.69%
Growth Streak

UCB Income Statement

Compare UCB to Peers and Sector

Metrics to compare
UCB
Peers
Sector
Relationship
P/E Ratio
31.7x21.0x−0.5x
PEG Ratio
0.680.370.00
Price/Book
4.5x4.1x2.6x
Price / LTM Sales
6.4x3.6x3.0x
Upside (Analyst Target)
15.4%7.5%58.6%
Fair Value Upside
Unlock14.6%10.2%Unlock

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet and Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops KYGEVVI (doxecitine/doxribtimine) for thymidine kinase 2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder, and RETT-Syndrome; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer’s disease; and UCB9741 for atopic dermatitis, non cystic fibrosis bronchiectasis, and chronic obstructive pulmonary disease. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Employees
9765
Market
Belgium

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
63.81M33.52%16.54B
Other Institutional Investors
67.63M35.53%17.53B
Public Companies & Retail Investors
58.93M30.96%15.27B
Total
190.36M100.00%49.34B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Financière de Tubize SA37.04%7,05,02,5541,82,74,262
FMR LLC7.60%1,44,59,73137,47,962

FAQ

What Is the UCB (UCB) Share Price Today?

The UCB share price today is 250.00.

What is the current UCB (UCB) share price and day range?

As of 16-06-2026, the UCB share price is 250.00, with a previous close of 259.20. The share price has ranged from 249.15 to 258.70 today, while the 52-week range spans from 153.65 to 289.50.

What Is the UCB Market Cap?

As of today, UCB market cap is 47.95B.

Does UCB Pay Dividends? What's The Current Dividend Yield?

The UCB dividend yield is 0.37%.

What Is the UCB (UCB) Share Price Target?

The average 12-month share price target for UCB is 288.95, with a high estimate of 340 and a low estimate of 195. 15 analysts recommend buying, while 1 suggest selling, with an overall rating of Buy and +15.58% Upside potential.

What Is UCB's Earnings Per Share (TTM)?

The UCB EPS (TTM) is 8.03.

When Is the Next UCB Earnings Date?

UCB will release its next earnings report on 30-07-2026.

From a Technical Analysis Perspective, Is UCB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

What Stock Exchange Does UCB Trade On?

UCB is listed and trades on the Brussels Stock Exchange.

What Is the Stock Symbol for UCB?

The stock symbol for UCB is "UCB."

How Many Times Has UCB Stock Split?

UCB has split 1 times.

How Many Employees Does UCB Have?

UCB has 9765 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.